Targeting the pathogenic role of interleukin 1{beta} in the progression of smoldering/indolent myeloma to active disease
- PMID: 19181642
- PMCID: PMC2664579
- DOI: 10.4065/84.2.105
Targeting the pathogenic role of interleukin 1{beta} in the progression of smoldering/indolent myeloma to active disease
Comment on
-
Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component.Mayo Clin Proc. 2009 Feb;84(2):114-22. doi: 10.4065/84.2.114. Mayo Clin Proc. 2009. PMID: 19181644 Free PMC article. Clinical Trial.
References
-
- Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007;356(25):2582-2590 - PubMed
-
- Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Ann Rev Immunol. 2009;27:519-550 - PubMed
-
- Lust JA, Donovan KA. The role of interleukin-1 beta in the pathogenesis of multiple myeloma. Hematol Oncol Clin North Am. 1999;13(6):1117-1125 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical